

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	<b>Application Number</b>		10524963	
	<b>Filing Date</b>		2005-02-18	
	<b>First Named Inventor</b>	David William Tonge		
	<b>Art Unit</b>			
	<b>Examiner Name</b>			
<b>Attorney Docket Number</b>		100815-1P US		

U.S. PATENTS						<a href="#">Remove</a>
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. [Add](#)

U.S. PATENT APPLICATION PUBLICATIONS						<a href="#">Remove</a>
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS							<a href="#">Remove</a>	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1	2007/010235	WO	A1	2007-01-25	AstraZeneca AB		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button. [Add](#)

NON-PATENT LITERATURE DOCUMENTS		<a href="#">Remove</a>	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Ts

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Not for submission under 37 CFR 1.99)

Application Number		10524963
Filing Date		2005-02-18
First Named Inventor	David William Tonge	
Art Unit		
Examiner Name		
Attorney Docket Number	100815-1P US	

1	PFLUG, et al., Defining the basis of an operational model for enhanced efficacy of combination therapy using an endothelin receptor antagonist and chemotherapeutic agents; EORTC Meeting October 2007.	<input type="checkbox"/>
2	ROSANO, L. et al., Combined Targeting of Endothelin A Receptor and the Epidermal Growth Factor Receptor in Ovarian Cancer Shows Enhanced Antitumor Activity, Cancer Research, July 1, 2007, Vol. 67(13).	<input type="checkbox"/>
3	ROSANO, L. et al., ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances cytotoxicity of paclitaxel in human ovarian carcinoma in vitro and in vivo. Proceedings of the American Association of Cancer Research 16-20 April 2005; 46, Abs 5830.	<input type="checkbox"/>
4	ROSANO, L. et al., ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo, Mol Cancer Ther., 2007, 2003-11. Jul;6(7).	<input type="checkbox"/>
5	WILLIAMS, E.D., The Combination of Specific Endothelin A Receptor Antagonist ZD4054 and Submaximal Bisphosphonate Pamidronate Prevents Soft-Tissue Metastasis, AAC-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, October 22-October 26, 2007, San Francisco, CA USA.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.